CXCR2 blockade

CXCR2 blockade has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest story, Nov 12, 2026: “Blood-cell mutations had opposite effects on breast tumors in mice”.

Intervention

1 paper studies it1 findingUpdated

1 new paper in 30 daysSee all 1 papers on CXCR2 blockade

At a glance

The findings reach mice, none yet in people. 1 lab.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab
  • Animals1

What did studies of CXCR2 blockade find?

1

Studies of CXCR2 blockade measured one outcome, tumor progression.

Tumor progression

downin mice1

1 study
  1. CXCR2 blockade decreases tumor progression in mice (Tet2-mutant CHIP mice with breast cancer).

    “Therapeutic blockade of IL-1R1 or CXCR2 reduced tumor progression in aged Tet2-mutant CHIP mice”

    AnimalsTet2-mutant CHIP mice with breast cancer

    Blood-cell mutations had opposite effects on breast tumors in mice

    bioRxivPreprint

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 11 paper in 12 months
bioRxiv

Blood-cell mutations had opposite effects on breast tumors in mice

As mice aged, mutations in the Dnmt3a gene prevented breast cancer progression, while mutations in the Tet2 gene drove it.As mice aged, mutations in the Dnmt3a gene prevented breast cancer progression, while mutations in the Tet2 gene drove it.

Preprint: mouse studyMechanisms